Shanghai Roche: Net profit of 1.56 billion yuan in 2025, with an annual plasma collection volume exceeding 2,000 tons

LightningPacketLoss · 2026-03-27T00:21:36+00:00

Shanghai Roche's 2025 annual report shows that the company's operating revenue and net profit attributable to shareholders both declined, reaching 7.35 billion yuan and 1.58 billion yuan respectively. The fourth quarter performance was particularly weak, with operating revenue down 32.5% year-on-year. Despite this, the company has made progress in pulp source and R&D innovation, and is advancing digital transformation to improve operational efficiency and market competitiveness.

LightningPacketLoss

2026-03-27 00:21:36

Abstract generation in progress

On March 26, Shanghai Roche Pharmaceuticals announced its 2025 annual report. The company’s operating revenue was 7.35 billion yuan, down 10.1% year-over-year; net profit attributable to shareholders was 1.58 billion yuan, down 28.1%; non-recurring net profit attributable to shareholders was 1.56 billion yuan, down 24.3%; net operating cash flow was -330 million yuan, an increase of 31.8% year-over-year; EPS (fully diluted) was 0.2376 yuan.

In the fourth quarter, the company’s operating revenue was 1.26 billion yuan, down 32.5% year-over-year; net profit attributable to shareholders was 106 million yuan, down 70.1%; non-recurring net profit attributable to shareholders was 75.28 million yuan, down 76.5%; EPS was 0.016 yuan.

As of the end of the fourth quarter, the company’s total assets were 37.781 billion yuan, an increase of 12.3% from the end of the previous year; net assets attributable to shareholders were 32.456 billion yuan, up 1.7% from the previous year.

The announcement mentioned a focus on R&D innovation and marketing transformation. The company made significant progress in plasma sourcing, with annual plasma collection exceeding 2,000 tons, an increase of over 8% year-over-year. Additionally, the company achieved important results in R&D, including the clinical trial phase of the innovative hemophilia drug SR604 injection, further enriching its product line.

Furthermore, the company continued its digital transformation, establishing a smart plasma station management system to improve operational efficiency and management effectiveness. During the reporting period, the company optimized its marketing model, expanded domestic and international markets, and enhanced its market competitiveness. Overall, the company is consolidating existing businesses while actively cultivating new growth points, promoting the coordinated development of operational quality and scale efficiency.

(Shanghai Roche Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Healthcare

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes